Iovance Biotherapeutics (IOVA) Operating Leases (2019 - 2026)

Iovance Biotherapeutics (IOVA) has reported Operating Leases for 8 consecutive years, with $43.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Leases fell 0.78% year-over-year to $43.9 million; the TTM figure through Mar 2026 stood at $43.9 million (down 0.78% YoY), while the FY2025 annual figure was $44.4 million, changed 0.08% from the prior year.
• Operating Leases retreated to $43.9 million in Q1 2026 per IOVA's latest filing, from $44.4 million in the prior quarter.
• Across five years, Operating Leases topped out at $73.0 million in Q2 2022 and bottomed at $43.9 million in Q1 2026.
• Historically, Operating Leases has averaged $60.1 million across 5 years, with a median of $68.0 million in 2023.
• Annual changes were most pronounced in 2022 — Operating Leases surged 55.83% — and 2025, when it sank 38.83%.
• Iovance Biotherapeutics' Operating Leases stood at $71.9 million in 2022, then slipped by 6.64% to $67.1 million in 2023, then sank by 33.87% to $44.4 million in 2024, then climbed by 0.08% to $44.4 million in 2025, then dropped by 1.18% to $43.9 million in 2026.
• Business Quant data shows IOVA's Operating Leases at $43.9 million in Q1 2026, $44.4 million in Q4 2025, and $45.2 million in Q3 2025.